Market closedNon-fractional
Renovaro/RENB
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Renovaro
Renovaro Inc formerly Renovaro Biosciences Inc is a biopharmaceutical company. It is engaged in the research and development of pharmaceutical and biological products for the treatment of HIV, HBV, and cancer with the intent to manufacture said products.
Ticker
RENB
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Los Angeles, United States
Employees
12
Website
renovarobio.com
Renovaro Metrics
BasicAdvanced
$184M
Market cap
-
P/E ratio
-$0.73
EPS
0.43
Beta
-
Dividend rate
Price and volume
Market cap
$184M
Beta
0.43
Financial strength
Current ratio
0.058
Quick ratio
0.015
Long term debt to equity
0.576
Total debt to equity
5.393
Interest coverage (TTM)
-24.03%
Management effectiveness
Return on assets (TTM)
-10.61%
Return on equity (TTM)
-45.95%
Valuation
Price to book
1.09
Price to tangible book (TTM)
-4.53
Price to free cash flow (TTM)
-8.508
Growth
Earnings per share change (TTM)
-62.53%
3-year earnings per share growth (CAGR)
36.20%
Renovaro Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$0
NaN%
Net income
-$17M
277.78%
Profit margin
0.00%
NaN%
Renovaro News
AllArticlesVideos
Renovaro, Inc. Announces $10 million in Equity Committed
GlobeNewsWire·1 month ago
Renovaro Inc. and Amsterdam UMC Cancer Center Poised to Advance Cancer Immunotherapy
GlobeNewsWire·2 months ago
Transforming Cancer Detection: RenovaroCube Introduces Flamingo, a novel AI model based on Fragmentomics
GlobeNewsWire·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Renovaro stock?
Renovaro (RENB) has a market cap of $184M as of July 27, 2024.
What is the P/E ratio for Renovaro stock?
The price to earnings (P/E) ratio for Renovaro (RENB) stock is 0 as of July 27, 2024.
Does Renovaro stock pay dividends?
No, Renovaro (RENB) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Renovaro dividend payment date?
Renovaro (RENB) stock does not pay dividends to its shareholders.
What is the beta indicator for Renovaro?
Renovaro (RENB) has a beta rating of 0.43. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell Renovaro stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.